aTyr Pharma Inc (OQ:LIFE)

Business Focus: Biotechnology & Medical Research

May 06, 2024 08:00 am ET
aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S.,...
May 02, 2024 04:00 pm ET
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter...
Apr 01, 2024 08:00 am ET
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two...
Mar 14, 2024 04:00 pm ET
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter...
Feb 28, 2024 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full...
Feb 21, 2024 08:00 am ET
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced plans to initiate an...
Jan 29, 2024 08:00 am ET
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present two posters...
Jan 18, 2024 08:00 am ET
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of...
Nov 13, 2023 08:00 am ET
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead...
Nov 10, 2023 08:31 am ET
Thinking about buying stock in Eurocell, Maia Biotechnology, Figs, aTyr Pharma, or Bloom Energy?
NEW YORK, Nov. 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ECEL, MAIA, FIGS, LIFE, and BE.
Nov 09, 2023 04:00 pm ET
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter...
Nov 01, 2023 08:00 am ET
aTyr Pharma to Present at November Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S.,...
Oct 31, 2023 08:00 am ET
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the...
Sep 11, 2023 08:00 am ET
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the results of a...
Aug 24, 2023 08:00 am ET
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Jill Broadfoot, Chief Financial Officer, will...
Aug 09, 2023 04:00 pm ET
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2023 results...
Jun 22, 2023 08:00 am ET
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug...
Jun 20, 2023 08:00 am ET
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present on its lead...
Jun 09, 2023 04:00 pm ET
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of...
Jun 06, 2023 08:00 am ET
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced multiple presentations at the...
May 25, 2023 08:00 am ET
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...
May 22, 2023 08:00 am ET
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for...
May 11, 2023 04:00 pm ET
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...
May 09, 2023 04:00 pm ET
aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2023 results and...
Apr 17, 2023 08:00 am ET
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation at the 2023 American Association...
Mar 30, 2023 08:00 am ET
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a review article, titled,...
Mar 21, 2023 08:00 am ET
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research,...
Mar 20, 2023 08:00 am ET
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, and the Foundation for Sarcoidosis Research (FSR), the...
Mar 09, 2023 04:00 pm ET
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year...
Mar 08, 2023 08:00 am ET
aTyr Pharma to Present at March Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor...
Mar 02, 2023 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year...
Mar 01, 2023 08:00 am ET
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided additional details regarding its plans to...
Feb 09, 2023 08:00 am ET
aTyr Pharma Announces Pricing of Public Offering of Common Stock
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten...
Feb 08, 2023 04:11 pm ET
aTyr Pharma Announces Commencement of Public Offering of Common Stock
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has commenced an underwritten public offering of...
Feb 06, 2023 08:00 am ET
aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that its partner Kyorin...
Jan 31, 2023 08:00 am ET
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the...
Jan 19, 2023 08:00 am ET
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a...
Jan 18, 2023 08:00 am ET
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug...
Dec 15, 2022 08:00 am ET
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform. The...
Nov 18, 2022 04:00 pm ET
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of...
Nov 10, 2022 04:00 pm ET
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate...
Nov 10, 2022 08:00 am ET
aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...
Nov 09, 2022 08:00 am ET
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results...
Nov 03, 2022 08:02 am ET
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financial...
Oct 25, 2022 08:00 am ET
aTyr Pharma to Present at the Jefferies London Healthcare Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...
Oct 11, 2022 08:00 am ET
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a...
Oct 04, 2022 08:00 am ET
aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...
Sep 29, 2022 08:00 am ET
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Patent and Trademark Office (USPTO) has...
Sep 27, 2022 08:00 am ET
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in the global...
Sep 16, 2022 08:35 am ET
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN...
Sep 13, 2022 08:00 am ET
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug...
Sep 12, 2022 08:35 am ET
Life Sciences Virtual Investor Conference Agenda Announced for September 15th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors,...
Sep 09, 2022 08:00 am ET
aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th
aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Ashlee Dunston, Director of...
Sep 06, 2022 08:00 am ET
aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...
Sep 01, 2022 08:00 am ET
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present a poster on Monday,...
Aug 15, 2022 04:00 pm ET
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate...
Aug 12, 2022 04:05 pm ET
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the Compensation Committee of aTyr’s Board...
Aug 11, 2022 08:03 am ET
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S....
Aug 04, 2022 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report second quarter 2022...
Jun 14, 2022 08:00 am ET
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that new findings from its platform will be...
Jun 13, 2022 08:00 am ET
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that Leslie A. Nangle, Ph.D., Vice President,...
Jun 01, 2022 08:00 am ET
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S. Shukla, M.D., M.S., President and...
May 17, 2022 08:00 am ET
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that clinical data for efzofitimod (ATYR1923), its...
May 16, 2022 08:00 am ET
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase platform, today announced a Phase 3 study evaluating the efficacy and safety of its...
May 13, 2022 04:00 pm ET
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the Compensation Committee of aTyr’s Board...
May 10, 2022 08:00 am ET
aTyr Pharma to Present at Upcoming Investor Conferences in May
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the company will present at two upcoming...
May 09, 2022 04:00 pm ET
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced first quarter 2022 results and provided a...
May 02, 2022 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2022 financial results and provide a...
Apr 13, 2022 08:00 am ET
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has...
Apr 11, 2022 08:00 am ET
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the 2022 American Association for Cancer...
Apr 01, 2022 08:00 am ET
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present clinical and...
Mar 25, 2022 04:00 pm ET
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the Compensation Committee of aTyr’s Board of Directors has...
Mar 14, 2022 04:00 pm ET
 aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced fourth quarter and full year 2021 results and provided a corporate...
Mar 10, 2022 08:03 am ET
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type B End-of-Phase 2...
Mar 08, 2022 04:35 pm ET
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American...
Mar 07, 2022 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2021 financial results...
Mar 03, 2022 08:00 am ET
aTyr Pharma to Present at Upcoming Investor Conferences in March
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Feb 23, 2022 08:00 am ET
aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Feb 07, 2022 08:00 am ET
aTyr Pharma to Present at BIO CEO & Investor Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Jan 13, 2022 08:03 am ET
 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the United States Adopted Names (USAN) Council and the World...
Jan 06, 2022 08:00 am ET
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has...
Jan 04, 2022 08:03 am ET
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate...
Dec 24, 2021 08:02 am ET
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human...
Dec 10, 2021 08:00 am ET
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a presentation at the Antibody Engineering & Therapeutics Conference...
Nov 30, 2021 08:00 am ET
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing...
Nov 12, 2021 08:00 am ET
aTyr Pharma to Present at Upcoming Investor Conferences in November
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Nov 10, 2021 04:00 pm ET
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced third quarter 2021 results and provided a corporate update. “The third...
Nov 09, 2021 08:05 am ET
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC)...
Nov 03, 2021 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide a...
Nov 02, 2021 09:00 am ET
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the...
Oct 12, 2021 08:32 am ET
Thinking about buying stock in Ocugen, aTyr Pharma, Nextplay Technologies, Aerie Pharmaceuticals, or Nutriband?
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, LIFE, NXTP, AERI, and NTRB.
Oct 11, 2021 08:00 am ET
aTyr Pharma to Participate in Piper Sandler Investor Lung Day
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Oct 06, 2021 08:00 am ET
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Robert W. Ashworth, Ph.D., to Vice President,...
Oct 01, 2021 08:01 am ET
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for...
Sep 20, 2021 04:07 pm ET
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the closing of an underwritten public offering of...
Sep 16, 2021 04:01 pm ET
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Sep 16, 2021 08:00 am ET
aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of...
Sep 15, 2021 04:01 pm ET
aTyr Pharma Announces Proposed Public Offering of Common Stock
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has commenced an underwritten public offering of...
Sep 14, 2021 08:53 am ET
Thinking about buying stock in aTyr Pharma, Progenity, AzurRx BioPharma, Rekor Systems, or Akerna Corp?
NEW YORK, Sept. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LIFE, PROG, AZRX, REKR, and KERN.
Sep 13, 2021 07:30 am ET
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced positive results from its Phase 1b/2a double-blind,...
Aug 10, 2021 04:00 pm ET
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced second quarter 2021 results and provided a corporate update. “We...
Aug 10, 2021 08:00 am ET
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, today announced that the company has expanded its research collaboration with The Ohio State University (OSU) to deepen the understanding of the immune mechanisms of...
Aug 09, 2021 08:00 am ET
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic candidate,...
Aug 03, 2021 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide a...
Jul 29, 2021 04:05 pm ET
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent...
Jul 08, 2021 08:00 am ET
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the last patient has completed their last visit in the company’s...
Jun 23, 2021 08:00 am ET
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a virtual Key Opinion Leader (KOL) event on...
Jun 10, 2021 04:30 pm ET
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the presentation of a poster at the Antibody Engineering & Therapeutics...
May 25, 2021 08:00 am ET
aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen, M.D., to the company’s Board of...
May 19, 2021 08:00 am ET
aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A session at...
May 13, 2021 04:05 pm ET
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced first quarter 2021 results and provided a corporate update. “During...
May 12, 2021 08:00 am ET
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company’s Hong Kong subsidiary, Pangu BioPharma Limited...
May 11, 2021 08:00 am ET
aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research. Dr....
May 06, 2021 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2021 financial results and provide a...
Apr 20, 2021 08:00 am ET
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and the Foundation for Sarcoidosis Research (FSR), the leading international nonprofit...
Apr 14, 2021 08:00 am ET
aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the...
Apr 09, 2021 08:00 am ET
aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced two poster presentations at the 2021 American Association for Cancer...
Apr 08, 2021 08:00 am ET
aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Andrea Wilson as a patient advisor to the company....
Mar 23, 2021 04:05 pm ET
aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced fourth quarter and full year 2020 results and provided a corporate...
Mar 19, 2021 08:00 am ET
aTyr Pharma to Present at the Benzinga Biotech Small Cap Conference
San Diego, California--(Newsfile Corp. - March 19, 2021) -  aTyr Pharma, Inc. (NASDAQ: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview and participate in live Q&A at the Benzinga Biotech Small Cap Conference, which is being held March 24 - 25, 2021 in a virtual format. Company management will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Mar 16, 2021 08:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 financial results...
Mar 15, 2021 08:00 am ET
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled...
Mar 11, 2021 08:00 am ET
aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American...
Mar 10, 2021 08:00 am ET
Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Judith Varner, Ph.D., as a scientific advisor to the...
Feb 25, 2021 08:00 am ET
aTyr Pharma to Present at March Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March....
Feb 11, 2021 08:00 am ET
aTyr Pharma Announces New tRNA Synthetase Discovery Programs
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has initiated two new discovery programs from its tRNA...
Feb 09, 2021 08:00 am ET
aTyr Pharma to Present at BIO CEO & Investor Digital Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Jan 25, 2021 08:00 am ET
aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A session at...
Jan 22, 2021 08:00 am ET
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and audio presentation at the upcoming...
Jan 14, 2021 08:00 am ET
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly...
Jan 07, 2021 07:00 am ET
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Jan 04, 2021 04:15 pm ET
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced positive topline results from its Phase 2 double-blind,...
Dec 21, 2020 07:00 am ET
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has completed the target enrollment in its Phase 1b/2a clinical...
Nov 12, 2020 04:05 pm ET
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced third quarter results and provided a corporate update. “Throughout...
Nov 11, 2020 07:00 am ET
aTyr Pharma Announces Publication in the Journal mAbs
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a publication highlighting new technological advances to isolate,...
Nov 10, 2020 07:00 am ET
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has identified receptor targets for two tRNA synthetases from...
Nov 05, 2020 07:00 am ET
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide a...
Oct 29, 2020 07:00 am ET
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has entered into a research collaboration with the Medical...
Oct 27, 2020 07:00 am ET
aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Oct 26, 2020 07:00 am ET
aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has completed enrollment in its Phase 2 clinical trial of its...
Oct 07, 2020 08:00 am ET
aTyr Pharma to Participate in October Virtual Investor Events
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor...
Sep 21, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Sep 15, 2020 07:00 am ET
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly...
Sep 14, 2020 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Sep 14, 2020 08:03 am ET
aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a Common Stock Purchase Agreement (the...
Sep 09, 2020 07:00 am ET
aTyr Pharma to Present at September Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in...
Sep 02, 2020 07:00 am ET
aTyr Pharma to Present at Life Sciences Investor Forum on September 17th
aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and...
Aug 13, 2020 04:00 pm ET
aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update. “While...
Aug 11, 2020 07:00 am ET
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a...
Aug 06, 2020 08:01 am ET
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and...
Jun 22, 2020 08:00 am ET
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for...
Jun 17, 2020 05:01 pm ET
aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today highlighted new external research demonstrating the involvement of Neuropilin...
Jun 15, 2020 07:00 am ET
aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has dosed the first patient in a Phase 2 study evaluating...
May 20, 2020 08:03 am ET
aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will present an abstract in a poster session at the 2020...
May 12, 2020 04:05 pm ET
aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced first quarter results and provided a corporate update. “As the...
May 06, 2020 08:03 am ET
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide...
May 05, 2020 08:03 am ET
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that two abstracts originally accepted for presentation at the 2020...
Apr 21, 2020 08:30 am ET
aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Mar 26, 2020 04:01 pm ET
aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced fourth quarter and full year 2019 results and provided a corporate...
Mar 24, 2020 08:30 am ET
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company’s Hong Kong subsidiary, Pangu BioPharma Limited...
Mar 19, 2020 04:05 pm ET
aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial...
Mar 17, 2020 08:30 am ET
Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advisor...
Mar 10, 2020 08:30 am ET
aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of...
Mar 03, 2020 08:00 am ET
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the...
Feb 27, 2020 08:00 am ET
aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a publication highlighting the essential role that histidyl tRNA...
Feb 06, 2020 09:00 am ET
aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares...
Jan 06, 2020 08:00 am ET
aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a collaboration and license agreement with...
Dec 12, 2019 08:00 am ET
aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the results of a pre-planned, blinded interim analysis of safety and...
Nov 14, 2019 04:01 pm ET
aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced third quarter 2019 results and provided a corporate update. “During...
Nov 13, 2019 08:00 am ET
aTyr Pharma to Present at the Stifel Healthcare Conference 2019
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla, President and Chief Executive Officer of...
Nov 07, 2019 08:00 am ET
aTyr Pharma to Announce Third Quarter Results on November 14th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report third quarter 2019 results after the market...
Oct 22, 2019 08:00 am ET
aTyr Pharma Announces Research Collaboration with Boston Children’s Hospital
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company has entered into a research collaboration with...
Sep 18, 2019 08:00 am ET
aTyr Pharma to Participate in September Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor conferences...
Sep 04, 2019 08:00 am ET
aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Aug 14, 2019 08:00 am ET
aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter 2019 results and provided a corporate update....
Aug 07, 2019 08:00 am ET
aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2019 results after the market...
Aug 06, 2019 08:00 am ET
Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the appointment of David Briscoe, MB, ChB, Director of the Transplant Research Program and Fellowship...
Jul 10, 2019 08:00 am ET
aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a Key Opinion Leader (KOL) call and webcast...
Jul 01, 2019 08:00 am ET
aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointments of Jane Gross, Ph.D. and Svetlana Lucas, Ph.D. to the...
Jun 28, 2019 04:05 pm ET
aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reverse stock...
May 13, 2019 04:05 pm ET
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced first quarter 2019 results and provided a corporate update. “During...
May 06, 2019 04:58 pm ET
aTyr Pharma to Announce First Quarter 2019 Results on May 13th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2019 results after the market...
Apr 16, 2019 08:00 am ET
aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will host a summit meeting on Neuropilin-2 (NRP-2)...
Apr 11, 2019 08:00 am ET
aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated...
Apr 08, 2019 04:00 pm ET
aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will present an abstract in a poster presentation...
Mar 25, 2019 04:00 pm ET
aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced fourth quarter and full year 2018 results and provided a corporate...
Mar 21, 2019 08:00 am ET
aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that data from its successful pilot study with the University of...
Mar 18, 2019 04:46 pm ET
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2018 financial...
Mar 11, 2019 08:00 am ET
aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option...
Mar 04, 2019 05:36 pm ET
aTyr Pharma Announces Participation at March Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical...
Feb 27, 2019 04:00 pm ET
aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the Keystone Symposia 2019 Conference in...
Feb 05, 2019 04:05 pm ET
aTyr Pharma to Present at the BIO CEO & Investor Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive...
Jan 30, 2019 04:00 pm ET
aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has expanded a successful pilot study and entered into a...
Jan 16, 2019 04:00 pm ET
Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today recognized the collaboration between its Hong Kong subsidiary, Pangu BioPharma...
Jan 02, 2019 07:37 pm ET
aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical...
Dec 04, 2018 08:00 am ET
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the initiation of a Phase 1b/2a study evaluating its lead candidate,...
Nov 28, 2018 08:16 pm ET
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief executive...
Nov 21, 2018 08:50 am ET
Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wilhelmina International, Inc. (NASDAQ:WHLM), Eyenovia, Inc....
Nov 13, 2018 04:05 pm ET
aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the third quarter ended September 30, 2018....
Nov 08, 2018 08:00 am ET
aTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its third quarter financial results on Tuesday,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.